<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269788</url>
  </required_header>
  <id_info>
    <org_study_id>89-02-30-10638</org_study_id>
    <nct_id>NCT01269788</nct_id>
  </id_info>
  <brief_title>Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial</brief_title>
  <official_title>Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastro-esophageal reflux disease (GERD) is highly prevalent, affecting up to 20% of the adult
      population in North America. Up to 70% of GERD patients have non-erosive reflux disease
      (NERD), a term used to describe symptoms suggestive of GERD in patients with no endoscopic
      evidence of erosive esophagitis. NERD represents a heterogeneous group of patients whom are
      sub classified according to 24 hours-PH monitoring results and also symptom-acid association
      analysis(Symptom Index,SI).

      Treatment of NERD can be a challenge for clinicians. According to the many studies , the
      pooled rate for symptomatic response after a period of proton pomp inhibitor(PPIs)therapy as
      the most frequently used drug, in NERD patients is lower than for erosive esophagitis
      patients. It is also shown that acid exposure is much lower in NERD patients than those with
      erosive esophagitis and NERD patients are less likely to exhibit a strong association between
      heartburn symptoms and acid reflux events than patients with erosive oesophagitis.

      Furthermore, beside the high economic burden, there are concerns about the adverse effects of
      long time administration of PPIs.

      Several hypothesis has been proposed to describe low response rate of NERD patients to PPIs.
      One of the most acceptable theories is that patients with anxiety or depression and
      psychological problems are at an increased risk of developing reflux symptoms. On the other
      hand, pain modulators such as sertraline, a selective serotonin reuptake inhibitor(SSRI), and
      other antidepressants have been shown to improve symptoms in patients with functional
      gastrointestinal disorders like non cardiac chest pain.

      According to the above-mentioned tips, the investigators hypothesize that antidepressants
      like fluoxetine, as an SSRI, may have beneficial effects in improving symptoms of NERD
      patients.

      The purpose of this study is to compare the effect of omeprazole with fluoxetine and placebo
      for treatment of NERD patients and its subgroups who all experience reflux symptoms and have
      normal endoscopic findings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>investigator-reported symptom severity</measure>
    <time_frame>6 weeks</time_frame>
    <description>symptom severity at beginning and 6 weeks after the study ,assessed by the standard questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient-reported symptom severity</measure>
    <time_frame>6 weeks</time_frame>
    <description>symptom severity reported by the patient in daily diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heartburn-free days</measure>
    <time_frame>6 weeks</time_frame>
    <description>percentage of 24-h heartburn-free days (days with neither daytime nor nighttime heartburn) during treatment assessed by daily diary</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>pH positive-omeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pH positive-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pH positive-fluoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pH negative-omeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pH negative-fluoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pH negative-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>20 mg , oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH positive-fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>20 mg , oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH positive-omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH positive-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>20 mg , oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH negative-omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>20 mg , oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH negative-fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral , daily 30 mins before breakfast, for 6 weeks</description>
    <arm_group_label>pH negative-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 18 and below 60 years old

          -  experiencing heartburn during last 6 months before inclusion

          -  experiencing heartburn during at least 4 of 7 days before inclusion

          -  presence of normal mucosa in upper gastrointestinal(GI) endoscopy which has been
             documented during 7 days before inclusion provided that the patient has not
             administered any PPI during last 30 days before inclusion

        Exclusion Criteria:

          -  inability to undergone upper GI endoscopy or PH monitoring

          -  presence of barret's esophagus or erosive esophagitis in upper GI endoscopy

          -  presence of active peptic ulcer disease or any disease which affects the absorption of
             drugs such as inflammatory bowel disease

          -  past history of esophageal or gastric surgery

          -  esophageal stricture which needs dilation

          -  administration of proton pomp inhibitors during 30 days before inclusion to the study

          -  administration of H2 blockers, anticholinergics, sucralfate and pro-kinetics during
             the assessments for eligibility and also during the study

          -  long time administration of non-steroidal anti-inflammatory drugs (NSAIDs)

          -  administration of neuroleptic or antidepressant drugs during 30 days before inclusion
             to the study

          -  known allergy to PPIs or SSRIs

          -  presence of significant systemic disease such as scleroderma , diabet mellitus ,
             peripheral and autonomic neuropathies and ...

          -  pregnancy for females

          -  presence of known psychiatric disorder such as depression , panic disorder or drug
             addiction according to the DSM-IV criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed Amir Mirbagheri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Faculty of medicine, Tehran university of medical sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Reza Ostovaneh, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arash Etemadi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasin Farrokhi Khajeh Pasha, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Behtash Saeidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaveh Hajifathalian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akbar Fotouhi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Mahmoud Eshagh hosseini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gasterointestinal endoscopy ward, Amir Alam hospital, Tehran university of medical sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009 Mar;104 Suppl 2:S27-32. doi: 10.1038/ajg.2009.49. Review. Erratum in: Am J Gastroenterol. 2009 Apr;104(4):1072. Am J Gastroenterol. 2009 Mar;104(2 Suppl):S39.</citation>
    <PMID>19262544</PMID>
  </reference>
  <reference>
    <citation>Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003 Feb 15;17(4):537-45.</citation>
    <PMID>12622762</PMID>
  </reference>
  <reference>
    <citation>Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:55-63. Review.</citation>
    <PMID>16042660</PMID>
  </reference>
  <reference>
    <citation>Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004 Aug;2(8):656-64. Review.</citation>
    <PMID>15290657</PMID>
  </reference>
  <reference>
    <citation>Bradley LA, Richter JE, Pulliam TJ, Haile JM, Scarinci IC, Schan CA, Dalton CB, Salley AN. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol. 1993 Jan;88(1):11-9.</citation>
    <PMID>8420248</PMID>
  </reference>
  <reference>
    <citation>DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther. 2006 Mar;23 Suppl 1:33-9. Review.</citation>
    <PMID>16483268</PMID>
  </reference>
  <reference>
    <citation>Venes DJ. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994 Sep 29;331(13):882; author reply 882-3.</citation>
    <PMID>8078547</PMID>
  </reference>
  <reference>
    <citation>Handa M, Mine K, Yamamoto H, Hayashi H, Tsuchida O, Kanazawa F, Kubo C. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 1999 Apr;28(3):228-32.</citation>
    <PMID>10192608</PMID>
  </reference>
  <reference>
    <citation>Varia I, Logue E, O'connor C, Newby K, Wagner HR, Davenport C, Rathey K, Krishnan KR. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000 Sep;140(3):367-72.</citation>
    <PMID>10966532</PMID>
  </reference>
  <reference>
    <citation>Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006 Feb 1;23(3):365-70.</citation>
    <PMID>16422995</PMID>
  </reference>
  <reference>
    <citation>Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004 Dec;13(10):1737-49.</citation>
    <PMID>15651544</PMID>
  </reference>
  <reference>
    <citation>Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1261-72. doi: 10.1111/j.1365-2036.2009.04013.x. Epub 2009 Apr 8.</citation>
    <PMID>19392864</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-erosive reflux disease</keyword>
  <keyword>heartburn</keyword>
  <keyword>functional</keyword>
  <keyword>Antidepressive Agents, Second-Generation</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Antidepressive Agents, Second-Generation</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

